Factor This Power Engineering
Live Events
DTECH⢠Events
POWERGEN®
Calendar
Resource Center
Webinars
Podcasts
White Papers
Contribute Content
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Project Development
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Resource Center
Webinars
Podcasts
Whitepapers
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exagen Inc. - Common Stock
(NQ:
XGN
)
3.110
+0.040 (+1.30%)
Streaming Delayed Price
Updated: 11:19 AM EDT, Mar 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Exagen Inc. - Common Stock
< Previous
1
2
3
Next >
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
March 10, 2026
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in Upcoming Investor Conferences
March 03, 2026
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
February 24, 2026
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Announces Select Preliminary 2025 Financial Results
January 11, 2026
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 11, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Strong Q3 2025 Results
November 04, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
October 23, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025
October 21, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in Third Quarter Investor Conferences
August 06, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Strong Q2 2025 Results
July 29, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Appoints Chas McKhann to Board of Directors
July 17, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
July 15, 2025
From
Exagen Inc.
Via
GlobeNewswire
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
June 23, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
May 09, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Prices Public Offering of Common Stock
May 08, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Announces Proposed Public Offering of Common Stock
May 07, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
May 05, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
April 28, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
April 21, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
March 11, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
February 25, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in Upcoming Investor Conferences
February 04, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
January 12, 2025
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
December 12, 2024
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
November 14, 2024
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 13, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. Reports Third Quarter 2024 Results
November 12, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
October 29, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
October 21, 2024
From
Exagen Inc.
Via
GlobeNewswire
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
September 04, 2024
From
Exagen Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
